MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesGlobeNewsWire • 04/30/24
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewsWire • 04/29/24
INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsGlobeNewsWire • 03/11/24
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8GlobeNewsWire • 03/05/24
Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 EarningsZacks Investment Research • 02/28/24
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateGlobeNewsWire • 02/27/24
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024GlobeNewsWire • 02/20/24
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®GlobeNewsWire • 02/15/24
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionGlobeNewsWire • 01/02/24
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/28/23
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 11/07/23
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 DiabetesGlobeNewsWire • 11/06/23
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023GlobeNewsWire • 10/31/23
Tyvaso DPI Is Breathing New Life Into MannKind's Balance Sheet (Rating Upgrade)Seeking Alpha • 10/18/23